Press Releases enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Market Closed - Nasdaq Other stock markets 21:00:00 27/06/2024 BST			5-day change	1st Jan Change
5.17 ^USD	+0.39%		+10.71%	+0.58%

06-21	EnVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial	CI
06-17	EnVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series	06-26	AQ
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024	06-24	AQ
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024	06-18	AQ
EnVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update	05-09	AQ
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium	04-25	AQ
New Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the 46th Annual Charing Cross Symposium on April 24, 2024	04-17	AQ
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer	04-10	AQ
EnVVeno Medical : Corporate Presentation	04-10	PU
EnVVeno Medical : Corporate Presentation	04-03	PU
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting	03-07	AQ
EnVVeno Medical : Corporate Presentation	03-04	PU
EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	03-01	AQ
Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024	02-21	AQ
EnVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium	12-15	AQ
EnVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium	11-17	AQ
EnVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update	27/10/23	AQ
EnVVeno Medical : Corporate Presentation	10/10/23	PU
EnVVeno Medical Announces New Expedited Development Plan for the enVVe Transcatheter Based Replacement Venous Valve	09/10/23	AQ
EnVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial	09/10/23	AQ
EnVVeno Medical Announces Private Placement of $28 Million	09/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Press Releases

Filters